Eventide Asset Management’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

Eventide Asset Management’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-27,000	Closed	-$2.03M	–	141
2020 Q1	$2.03M	Hold	27,000	–	–	0.07%	109
2019 Q4	$3.71M	Hold	27,000	–	–	0.1%	86
2019 Q3	$3.21M	Hold	27,000	–	–	0.11%	88
2019 Q2	$3.78M	Hold	27,000	–	–	0.11%	88
2019 Q1	$4.83M	Hold	27,000	–	–	0.17%	91
2018 Q4	$4.25M	Buy	+27,000	New	+$4.03M	0.19%	89

Other funds holding ORTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Eventide Asset Management's ORTX Position: Q2 2020 in Review

Eventide Asset Management sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q2 2020, closing a stake of 27,000 shares — an estimated $2.03M sold.

Eventide Asset Management first reported a position in ORTX in Q4 2018 and held it in 6 quarters. The position peaked at $4.83M in Q1 2019. 81 funds tracked by Wall St. Rank hold ORTX as of Q2 2020.

Eventide Asset Management reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q2 2020 after selling out during the quarter.
Eventide Asset Management sold 27,000 Orchard Therapeutics plc American Depositary Shares shares in Q2 2020, an estimated $2.03M.
Eventide Asset Management first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2018 and held it in 6 quarters.
Eventide Asset Management's Orchard Therapeutics plc American Depositary Shares position peaked at $4.83M in Q1 2019.
81 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q2 2020.

Based on Eventide Asset Management's 13F filing for Q2 2020, filed 14 Aug 2020.